The PD-1 Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“PD-1 Non-Small Cell Lung Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PD-1 Non-Small Cell Lung Cancer Market.

Some of the key takeaways from the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Report:

• Companies across the globe are diligently working toward developing novel PD-1 Non-Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years. 
• PD-1 Non-Small Cell Lung Cancer companies working in the treatment market are  Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corporation, Akeso Biopharma, Arcus Biosciences, and others, are developing therapies for the PD-1 Non-Small Cell Lung Cancer treatment 

• Emerging PD-1 Non-Small Cell Lung Cancer therapies such as – GB226, BA-1104, PF-06801591, AZD2936, HX008, Dostarlimab, INCMGA00012, AK-112, Zimberelimab, and others are expected to have a significant impact on the PD-1 Non-Small Cell Lung Cancer market in the coming years.   
• In February 2021, Arcus Biosciences initiated a Randomized Phase III Open-label Study will Evaluate the Efficacy of Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined withAB154 in Front-Line, PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• In May 2020, Arcus Biosciences initiated an open-label Phase II study in participants with non-small cell lung cancer which will assess the safety, efficacy and tolerability of zimberelimab as monotherapy and in combination with other immunotherapeutic across multiple treatment arms

PD-1 Non-Small Cell Lung Cancer Overview

Lung cancer remains a leading cause of cancer-related mortality worldwide with the poor prognosis. Encouragingly, immune checkpoint blockade targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has dramatically changed the landscape for treatments in patients with non-small-cell lung cancer (NSCLC).

Get a Free Sample PDF Report to know more about PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight

Emerging PD-1 Non-Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:

• GB226: Genor Biopharma
• BA-1104: Shandong Boan Biotechnology
• PF-06801591: Pfizer
• AZD2936: AstraZeneca
• HX008: Lepu Biopharma
• Dostarlimab: GlaxoSmithKline
• INCMGA00012: Incyte Corporation
• AK-112: Akeso Biopharma
• Zimberelimab: Arcus Biosciences

Route of Administration

PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

• PD-1 Non-Small Cell Lung Cancer Assessment by Product Type
• PD-1 Non-Small Cell Lung Cancer By Stage and Product Type
• PD-1 Non-Small Cell Lung Cancer Assessment by Route of Administration
• PD-1 Non-Small Cell Lung Cancer By Stage and Route of Administration
• PD-1 Non-Small Cell Lung Cancer Assessment by Molecule Type
• PD-1 Non-Small Cell Lung Cancer by Stage and Molecule Type

DelveInsight’s PD-1 Non-Small Cell Lung Cancer Report covers around 30+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further PD-1 Non-Small Cell Lung Cancer product details are provided in the report. Download the PD-1 Non-Small Cell Lung Cancer pipeline report to learn more about the emerging PD-1 Non-Small Cell Lung Cancer therapies

Some of the key companies in the PD-1 Non-Small Cell Lung Cancer Therapeutics Market include:

Key companies developing therapies for PD-1 Non-Small Cell Lung Cancer are – Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Bristol Myers Squibb, Sanofi, IO Biotech, Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, and others.

PD-1 Non-Small Cell Lung Cancer Pipeline Analysis:

The PD-1 Non-Small Cell Lung Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of PD-1 Non-Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 Non-Small Cell Lung Cancer Treatment.
• PD-1 Non-Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• PD-1 Non-Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1 Non-Small Cell Lung Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about PD-1 Non-Small Cell Lung Cancer drugs and therapies

PD-1 Non-Small Cell Lung Cancer Pipeline Market Drivers 

• Increase in Patient Burden, development of Efficient Novel Treatments, increasing healthcare expenditures are some of the important factors that are fueling the PD-1 Non-Small Cell Lung Cancer Market.

PD-1 Non-Small Cell Lung Cancer Pipeline Market Barriers

• However, Uncertainty about the clinical response to PD-1/PD-L1 blockade therapy in NSCLC, NSCLC with driver mutations represent a challenging population and other factors are creating obstacles in the PD-1 Non-Small Cell Lung Cancer Market growth.

Scope of PD-1 Non-Small Cell Lung Cancer Pipeline Drug Insight    

• Coverage: Global
• Key PD-1 Non-Small Cell Lung Cancer Companies: Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corporation, Akeso Biopharma, Arcus Biosciences, and others
• Key PD-1 Non-Small Cell Lung Cancer Therapies: GB226, BA-1104, PF-06801591, AZD2936, HX008, Dostarlimab, INCMGA00012, AK-112, Zimberelimab, and others
• PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment: PD-1 Non-Small Cell Lung Cancer current marketed and PD-1 Non-Small Cell Lung Cancer emerging therapies
• PD-1 Non-Small Cell Lung Cancer Market Dynamics: PD-1 Non-Small Cell Lung Cancer market drivers and PD-1 Non-Small Cell Lung Cancer market barriers 

Request for Sample PDF Report for PD-1 Non-Small Cell Lung Cancer Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services